Patents by Inventor Roberto Magliozzi

Roberto Magliozzi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FIXaxFX bispecific antibody with common light chain
    Patent number: 11976135
    Abstract: Bispecific antigen binding molecules (e.g., antibodies) that bind blood clotting factors, factor IXa (FIXa) and factor X (FX), and enhance the FIXa-catalysed activation of FX to FXa. Use of the bispecific antigen binding molecules to control bleeding, by replacing natural cofactor FVIIIa which is deficient in patients with haemophilia A.
    Type: Grant
    Filed: October 6, 2020
    Date of Patent: May 7, 2024
    Assignee: KYMAB LIMITED
    Inventors: Wei Wang, E-Chiang Lee, John Kenneth Blackwood, Roberto Magliozzi
  • Bispecific antibodies for factor IX and factor X
    Patent number: 11919969
    Abstract: Bispecific antigen binding molecules (e.g., antibodies) that bind blood clotting factors, factor IXa (FIXa) and factor X (FX), and enhance the FIXa-catalysed activation of FX to FXa. Use of the bispecific antigen binding molecules to control bleeding, by replacing natural cofactor FVIIIa which is deficient in patients with haemophilia A.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: March 5, 2024
    Assignee: KYMAB LIMITED
    Inventors: Wei Wang, E-Chiang Lee, John Kenneth Blackwood, Roberto Magliozzi
  • FIXAXFX BISPECIFIC ANTIBODY WITH COMMON LIGHT CHAIN
    Publication number: 20220064327
    Abstract: Bispecific antigen binding molecules (e.g., antibodies) that bind blood clotting factors, factor IXa (FIXa) and factor X (FX), and enhance the FIXa-catalysed activation of FX to FXa. Use of the bispecific antigen binding molecules to control bleeding, by replacing natural cofactor FVIIIa which is deficient in patients with haemophilia A.
    Type: Application
    Filed: December 20, 2019
    Publication date: March 3, 2022
    Inventors: Wei WANG, E-Chiang LEE, John Kenneth BLACKWOOD, Roberto MAGLIOZZI
  • FIXaxFX Bispecific Antibody with Common Light Chain
    Publication number: 20210101997
    Abstract: Bispecific antigen binding molecules (e.g., antibodies) that bind blood clotting factors, factor IXa (FIXa) and factor X (FX), and enhance the FIXa-catalysed activation of FX to FXa. Use of the bispecific antigen binding molecules to control bleeding, by replacing natural cofactor FVIIIa which is deficient in patients with haemophilia A.
    Type: Application
    Filed: October 6, 2020
    Publication date: April 8, 2021
    Inventors: Wei Wang, E-Chiang Lee, John Kenneth Blackwood, Roberto Magliozzi
  • FIXaxFX bispecific antibody with common light chain
    Patent number: 10815308
    Abstract: Bispecific antigen binding molecules (e.g., antibodies) that bind blood clotting factors, factor IXa (FIXa) and factor X (FX), and enhance the FIXa-catalysed activation of FX to FXa. Use of the bispecific antigen binding molecules to control bleeding, by replacing natural cofactor FVIIIa which is deficient in patients with haemophilia A.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: October 27, 2020
    Assignee: KYMAB LIMITED
    Inventors: Wei Wang, E-Chiang Lee, John Kenneth Blackwood, Roberto Magliozzi
  • CELLS, VERTEBRATES, POPULATIONS & METHODS
    Publication number: 20200214274
    Abstract: The invention relates to cells and non-human vertebrates for producing antibody chains (eg, truly common L or H chains), in particular for use in producing multi-specific antibodies useful for therapy or diagnosis.
    Type: Application
    Filed: December 19, 2019
    Publication date: July 9, 2020
    Inventors: E-Chiang Lee, Wei Wang, John Kenneth Blackwood, Roberto Magliozzi
  • FIXaxFX Bispecific Antibody with Common Light Chain
    Publication number: 20200199250
    Abstract: Bispecific antigen binding molecules (e.g., antibodies) that bind blood clotting factors, factor IXa (FIXa) and factor X (FX), and enhance the FIXa-catalysed activation of FX to FXa. Use of the bispecific antigen binding molecules to control bleeding, by replacing natural cofactor FVIIIa which is deficient in patients with haemophilia A.
    Type: Application
    Filed: December 20, 2019
    Publication date: June 25, 2020
    Inventors: Wei Wang, E-Chiang Lee, John Kenneth Blackwood, Roberto Magliozzi
  • BISPECIFIC ANTIBODIES FOR FACTOR IX AND FACTOR X
    Publication number: 20200148787
    Abstract: Bispecific antigen binding molecules (e.g., antibodies) that bind blood clotting factors, factor IXa (FIXa) and factor X (FX), and enhance the FIXa-catalysed activation of FX to FXa. Use of the bispecific antigen binding molecules to control bleeding, by replacing natural cofactor FVIIIa which is deficient in patients with haemophilia A.
    Type: Application
    Filed: June 22, 2018
    Publication date: May 14, 2020
    Inventors: Wei Wang, E-Chiang Lee, John Kenneth Blackwood, Roberto Magliozzi